CytoDyn CEO responds to share price rise as investors get excited about leronlimab
CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive Investors he's optimistic about results the company has seen in pre-clinical studies relating to a liver disease known as NASH. However, he's not sure how much CymaBay Therapeutics Inc's (NASDAQ:CBAY) disappointing mid-stage trial results in NASH contributed to pushing up CytoDyn's stock.
Pourhassan also touches on other developments within the Washington-based company including timelines to submit its BLA and recent fundraising efforts.
Quick facts: CytoDyn
Market Cap: $141.32 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE